Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • A look at upcoming bank reporting
    • Opinion

    A look at upcoming bank reporting

    Last week we saw an earnings report from Bank of Queensland, the first of the domestic banks to report earnings in the October/November period. The report was largely in-line with analysts’ expectations, but the stock fell on the day and has continued lower since then. Perhaps the market was optimistic that results would surprise toRead More
    Public
  • The long road ahead for Seven West Media
    • Opinion

    The long road ahead for Seven West Media

    Emerald Financial Rating: Medium-term Sell Price at time of publication: $0.42 The Australian media ranks have once again had their feathers rustled earlier in the year following the resignation of Seven West Media CEO Tim Worner just five days before he had been due to deliver the Groups FY19 financial results. With the timing ofRead More
    Public
  • Australia’s green whistle pain relief winning over Europeans
    • News

    Australia’s green whistle pain relief winning over Europeans

    Carried and administered by Australian paramedics for decades, the green whistle pain reliever has been on the Australian market for years but clinical trials in Europe have now revealed Penthrox® to be a superior pain relief product than traditional treatments of morphine (IV), paracetamol, ketoprofen and NSAIDS.  Marketed as Penthrox® with the key ingredient of

    Read More
    Public
  • Investing Through Economic Uncertainty – How The Healthcare Sector Has Flourished
    • Opinion

    Investing Through Economic Uncertainty – How The Healthcare Sector Has Flourished

    Typically during a recession, consumers reduce their spending. But people can’t stop getting sick, becoming injured, or requiring health care products and services, just because there is a downshift in the economy. So what happens to the healthcare sector when there is a recession? During the Global Financial Crisis between 2007-2009, the ASX 200 recorded

    Read More
    Public
  • Noxopharm achieves significant pain relief for late-stage prostate cancer patients
    • News

    Noxopharm achieves significant pain relief for late-stage prostate cancer patients

    Prostate cancer patients could soon be in for potentially good news after clinical stage-drug development company, Noxopharm (ASX: NOX) reported interim data indicating effective anti-cancer responses from patients receiving treatment for late-stage prostate cancer.  To date, the data from the study (DARRT-1) found that 80% of patients showed no further progression in their disease after

    Read More
    Public
  • WineDepot signs foundation client, Australia’s largest family-owned winery
    • News

    WineDepot signs foundation client, Australia’s largest family-owned winery

    Tech newcomer Digital Wine Ventures (ASX: DW8) has hit the ground running with the signing of Casella Family Brands, Australia largest family-owned winery, as a foundation client for their one-stop-shop WineDepot platform.  Launched in September 2019, WineDepot is a B2B cloud-based platform which aims to connect wine producers, distributors, importers and retailers enabling producers a

    Read More
    Public
  • «
  • ‹
  • 647
  • 648
  • 649
  • 650
  • 651
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.